Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Related Posts
Zhang D, Tsai K, Santana C, Javaherian K, Lee M, Bergsneider M, Kim W, Wang MB, Vinters HV, Yan W, Heaney AP. Genetic profiling of[...]
Songo J, Whitehead HS, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout J, Moses A, Hoffman RM, Moucheraud C. Uptake of the COVID-19[...]
Cho DJ, Bokhoor PI, Dermenchyan A, Brownell N, Delavin NL, Furlong S, Hoo J, Tibbe T, Chen LY, Vangala S, Waterman BA, Han M, Fonarow[...]